Medtronic, Inc. : Medtronic Receives 'CE' Mark for Sentrant Introducer Sheath, Complementing Market-Leading Aortic Stent Grafts

Medtronic, Inc. : Medtronic Receives 'CE' Mark for Sentrant Introducer Sheath,
               Complementing Market-Leading Aortic Stent Grafts

Medtronic, Inc.

   Distinguishing Features of New Accessory for Endovascular Interventions
 Include Optimal Seal for Superior Hemostasis and Reinforced Coil for Proven
                               Kink Resistance

MINNEAPOLIS-- April 4, 2013 -- Complementing its market-leading portfolio of
stent grafts for the endovascular repair of aortic aneurysms and related
conditions, Medtronic, Inc. (NYSE: MDT) announced today that the Sentrant
Introducer Sheath has received the CE (Conformité Européenne) mark and will
soon be launched internationally.

The Sentrant Introducer Sheath is designed for use with Medtronic's Endurant
II AAA and Valiant Captivia Stent Graft Systems, the market-leading devices in
their product categories worldwide, and can also be used with similar devices
for endovascular repair. Inserted at the access site in the patient's femoral
artery, the tapered tube is advanced up into the iliac arteries to facilitate
the implant procedure, enabling smooth passage of the stent graft delivery
system and accessory devices en route to the treatment site in the aorta.

Distinguishing features of the Sentrant Introducer Sheath include:

  oOptimal seal compared to competitive sheaths for superior hemostasis
    during the procedure.
  oReinforced coil for proven kink resistance.
  oHydrophilic coating and flexibility for easy tracking through tortuous and
    calcified iliacs.
  oRadiopaque marker band for clear visibility.
  oDilator locking mechanism for secure positioning.

To accommodate a range of anatomies, the Sentrant Introducer Sheath is made in
diameters of 12-26 French and lengths of 28cm and 64cm. Compatible with the
Archer Super Stiff Guidewire and the Reliant Stent Graft Balloon Catheter, it
expands Medtronic's accessories toolkit for endovascular aortic interventions.

Medtronic's complete portfolio of stent grafts and related accessories will be
on display during the Charing Cross symposium in London from April 6-9.

In collaboration with leading clinicians, researchers and scientists
worldwide, Medtronic offers the broadest range of innovative medical
technology for the interventional and surgical treatment of cardiovascular
disease and cardiac arrhythmias. The company strives to offer products and
services that deliver clinical and economic value to healthcare consumers and
providers around the world.

Medtronic, Inc. (, headquartered in Minneapolis, is the
global leader in medical technology -- alleviating pain, restoring health and
extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic's periodic reports on file with the Securities
and Exchange Commission. Actual results may differ materially from anticipated

                                   - end -

Joseph McGrath
Public Relations

Jeff Warren
Investor Relations


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Medtronic, Inc. via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.